First description of an acinic cell carcinoma of the breast in a BRCA1 mutation carrier: A case report

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Ripamonti, Carla B ^a   Colombo, Mara ^a   Mondini, Patrizia ^a   Siranoush, Manoukian ^a   Peissel, Bernard ^a   Bernard, Loris ^b,c   Radice, Paolo ^a,d   Carcangiu, Maria Luisa ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c Cogentech Cancer Genetic Test Laboratory ^*  (Italy)

^d FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

Author keywords

Acinic cell carcinoma; BRCA1; Breast cancer; TP53 mutation; Triple negative

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL MEMBRANE ANTIGEN; ESTROGEN RECEPTOR; FLUOROURACIL; GONADORELIN DERIVATIVE; METHOTREXATE; PROGESTERONE RECEPTOR; PROTEIN P53; PROTEIN S 100; TAMOXIFEN;

ACINAR CELL CARCINOMA; ADULT; ALLELE; ARTICLE; BREAST CARCINOMA; CASE REPORT; ECHOGRAPHY; EXON; FEMALE; GENE AMPLIFICATION; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAMMOGRAPHY; MASTECTOMY; MICROSATELLITE MARKER; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; SENTINEL LYMPH NODE BIOPSY; SEQUENCE ANALYSIS; SOMATIC MUTATION; TP53 GENE; TUMOR SUPPRESSOR GENE; WILD TYPE;

ADULT; BREAST NEOPLASMS; CARCINOMA, ACINAR CELL; CARCINOMA, DUCTAL, BREAST; FEMALE; GENES, BRCA1; HETEROZYGOTE; HUMANS; MUTATION; NEOPLASMS, SECOND PRIMARY; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84873025718     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-46     Document Type: Article

References (51)

1. Hoffman HT, Karnell LH, Robinson RA, Pinkston JA, Menck HR. National cancer data base report on cancer of the head and neck: acinic cell carcinoma. Head Neck 1999, 21:297-309. 10.1002/(SICI)1097-0347(199907)21:4<297::AID-HED2>3.0.CO;2-R, 10376748.
2. Ordóñez NG. Pancreatic acinar cell carcinoma. Adv Anat Pathol 2001, 8:144-159. 10.1097/00125480-200105000-00003, 11345238.
3. Holen KD, Klimstra DS, Hummer A, Gonen M, Conlon K, Brennan M, Saltz LB. Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors. J Clin Oncol 2002, 15:4673-4678.
4. De Rosa G, Zeppa P, Tranfa F, Bonavolontà G. Acinic cell carcinoma arising in a lacrimal gland. First case report. Cancer 1988, 57:1988-1891.
5. Rodriguez J, Diment J, Lombardi L, Dominoni F, Tench W, Rosai J. Combined typical carcinoid and acinic cell tumor of the lung: a heretofore unreported occurrence. Hum Pathol 2003, 34:1061-1065. 10.1053/S0046-8177(03)00347-2, 14608543.
6. Hervieu V, Lombard-Bohas C, Dumortier J, Boillot O, Scoazec JY. Primary acinar cell carcinoma of the liver. Virchows Arch 2008, 452:337-341. 10.1007/s00428-007-0556-7, 18193278.
7. Ambrosini-Spaltro A, Potì O, De Palma M, Filotico M. Pancreatic-type acinar cell carcinoma of the stomach beneath a focus of pancreatic metaplasia of the gastric mucosa. Hum Pathol 2009, 40:746-749. 10.1016/j.humpath.2008.10.006, 19144387.
8. Agaimy A, Kaiser A, Becker K, Bräsen JH, Wünsch PH, Adsay NV, Klöppel G. Pancreatic-type acinar cell carcinoma of the liver: a clinicopathologic study of four patients. Mod Pathol 2011, 24:1620-1626. 10.1038/modpathol.2011.127, 21841771.
9. Pesci A, Castelli P, Facci E, Romano L, Zamboni G. Primary retroperitoneal acinar cell cystadenoma. Hum Pathol 2012, 43:446-450. 10.1016/j.humpath.2011.05.015, 21840569.
10. Roncaroli F, Lamovec J, Zidar A, Eusebi V. Acinic cell-like carcinoma of the breast. Virchows Arch 1996, 429:69-74.
11. Shimao K, Haga S, Shimizu T, Imamura H, Watanabe O, Kinoshita J, Nagumo H, Utada Y, Okabe T, Kajiwara T, Oshibe N, Aiba M. Acinic cell adenocarcinoma arising in the breast of a young male: a clinicopathological. Immunohistochemical and ultrastructural study. Breast Cancer 1998, 5:77-81. 10.1007/BF02967419, 11091630.
12. Damiani S, Pasquinelli G, Lamovec J, Peterse JL, Eusebi V. Acinic cell carcinoma of the breast: an immunohistochemical and ultrastructural study. Virchows Arch 2000, 437:74-81. 10.1007/s004280000206, 10963383.
13. Schmitt FC, Ribeiro CA, Alvarenga S, Lopes JM. Primary acinic cell-like carcinoma of the breast-a variant with good prognosis?. Histopathology 2000, 3:286-289.
14. Coyne JD, Dervan PA. Primary acinic cell carcinoma of the breast. J Clin Pathol 2002, 55:545-547. 10.1136/jcp.55.7.545, 1769684, 12101208.
15. Elster EA, Markusic J, Ball R, Soballe P, Henry M, Louie A, Clare S. Primary acinic cell carcinoma of the breast. Am Surg 2002, 68:993-995.
16. Peintinger F, Leibl S, Reitsamer R, Moinfar F. Primary acinic cell carcinoma of the breast: a case report with long-term follow-up and review of the literature. Histopathology 2004, 45:645-648. 10.1111/j.1365-2559.2004.01957.x, 15569060.
17. Tanahashi C, Yabuki S, Akamine N, Yatabe Y, Ichihara S. Pure acinic cell carcinoma of the breast in an 80-year-old Japanese woman. Pathol Int 2007, 57:43-46. 10.1111/j.1440-1827.2007.02055.x, 17199742.
18. Chang ED, Lee EJ, Lee AW, Kim JS, Kang CS. Primary acinic cell carcinoma of the breast: a case report with an immunohistochemical and ultrastructural studies. J Breast Cancer 2011, 14:160-164. 10.4048/jbc.2011.14.2.160, 3148534, 21847414.
19. Sakuma T, Mimura A, Tanigawa N, Takamizu R. Fine needle aspiration cytology of acinic cell carcinoma of the breast. Cytopathology 2012, Epub ahead of print.
20. Pia-Foschini M, Reis-Filho JS, Eusebi V, Lakhani SR. Salivary gland-like tumours of the breast: surgical and molecular pathology. J Clin Pathol 2003, 56:497-506. 10.1136/jcp.56.7.497, 1769991, 12835294.
21. Foschini MP, Krausz T. Salivary gland-type tumors of the breast: a spectrum of benign and malignant tumors including "triple negative carcinomas" of low malignant potential. Semin Diagn Pathol 2010, 27:77-90. 10.1053/j.semdp.2009.12.007, 20306833.
22. Stratton MR, Rahman N. The emerging landscape of breast cancer susceptibility. Nat Genet 2008, 40:17-22. 10.1038/ng.2007.53, 18163131.
23. Mavaddat N, Rebbeck TR, Lakhani SR, Easton DF, Antoniou AC. Incorporating tumour pathology information into breast cancer risk prediction algorithms. Breast Cancer Res 2010, 12:R28. 10.1186/bcr2576, 2917017, 20482762.
24. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjäkoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003, 72:1117-1130. 10.1086/375033, 1180265, 12677558.
25. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007, 25:1329-1333. 10.1200/JCO.2006.09.1066, 2267287, 17416853.
26. Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002, 20:2310-2318. 10.1200/JCO.2002.09.023, 11981002.
27. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, Bishop T, Benitez J, Rivas C, Bignon YJ, Chang-Claude J, Hamann U, Cornelisse CJ, Devilee P, Beckmann MW, Nestle-Krämling C, Daly PA, Haites N, Varley J, Lalloo F, Evans G, Maugard C, Meijers-Heijboer H, Klijn JG, Olah E, Gusterson BA, Pilotti S, Radice P, Scherneck S, Sobol H, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005, 11:5175-5180. 10.1158/1078-0432.CCR-04-2424, 16033833.
28. Palacios J, Honrado E, Osorio A, Cazorla A, Sarrió D, Barroso A, Rodríguez S, Cigudosa JC, Diez O, Alonso C, Lerma E, Dopazo J, Rivas C, Benítez J. Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res Treat 2005, 90:5-14. 10.1007/s10549-004-1536-0, 15770521.
29. Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Spurdle A, Robson M, Sherman M, Mulligan AM, Couch FJ, Engel C, McGuffog L. Consortium of Investigators of Modifiers of BRCA1/2: Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 2012, 21:134-147. 10.1158/1055-9965.EPI-11-0775, 3272407, 22144499.
30. Honrado E, Benítez J, Palacios J. The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. Mod Pathol 2005, 18:1305-1320. 10.1038/modpathol.3800453, 15933754.
31. Greenblatt MS, Chappuis PO, Bond JP, Hamel N, Foulkes WD. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution. Cancer Res 2001, 61:4092-4097.
32. Colombo M, Giarola M, Mariani L, Ripamonti CB, De Benedetti V, Sardella M, Losa M, Manoukian S, Peissel B, Pierotti MA, Pilotti S, Radice P. Cyclin D1 expression analysis in familial breast cancers may discriminate BRCAX from BRCA2-linked cases. Mod Pathol 2008, 21:1262-1270. 10.1038/modpathol.2008.43, 18327210.
33. Yang Y, Swaminathan S, Martin BK, Sharan SK. Aberrant splicing induced by missense mutations in BRCA1: clues from a humanized mouse model. Hum Mol Genet 2003, 12:2121-2131. 10.1093/hmg/ddg222, 12915465.
34. Easton DF, Deffenbaugh AM, Pruss D, Frye C, Wenstrup RJ, Allen-Brady K, Tavtigian SV, Monteiro AN, Iversen ES, Couch FJ, Goldgar DE. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet 2007, 8:873-883.
35. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007, 28:622-629. 10.1002/humu.20495, 17311302.
36. Lowery MA, Kelsen DP, Stadler ZK, Yu KH, Janjigian YY, Ludwig E, D'Adamo DR, Salo-Mullen E, Robson ME, Allen PJ, Kurtz RC, O'Reilly EM. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist 2011, 16:1397-1402. 10.1634/theoncologist.2011-0185, 3228075, 21934105.
37. Skoulidis F, Cassidy LD, Pisupati V, Jonasson JG, Bjarnason H, Eyfjord JE, Karreth FA, Lim M, Barber LM, Clatworthy SA, Davies SE, Olive KP, Tuveson DA, Venkitaraman AR. Germline Brca2 heterozygosity promotes Kras(G12D)-driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell 2010, 18:499-509. 10.1016/j.ccr.2010.10.015, 21056012.
38. Klümpen HJ, Queiroz KC, Spek CA, van Noesel CJ, Brink HC, de Leng WW, de Wilde RF, Mathus-Vliegen EM, Offerhaus GJ, Alleman MA, Westermann AM, Richel DJ. mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome. J Clin Oncol 2011, 29:e150-153. 10.1200/JCO.2010.32.7825, 21189378.
39. de Wilde RF, Ottenhof NA, Jansen M, Morsink FH, de Leng WW, Offerhaus GJ, Brosens LA. Analysis of LKB1 mutations and other molecular alterations in pancreatic acinar cell carcinoma. Mod Pathol 2011, 24:1229-1236. 10.1038/modpathol.2011.83, 21572398.
40. Lowery MA, Klimstra DS, Shia J, Yu KH, Allen PJ, Brennan MF, O'Reilly EM. Acinar cell carcinoma of the pancreas: new genetic and treatment insights into a rare malignancy. Oncologist 2011, 16:1714-1720. 10.1634/theoncologist.2011-0231, 3248770, 22042785.
41. Gaujoux S, Tissier F, Ragazzon B, Rebours V, Saloustros E, Perlemoine K, Vincent-Dejean C, Meurette G, Cassagnau E, Dousset B, Bertagna X, Horvath A, Terris B, Carney JA, Stratakis CA, Bertherat J. Pancreatic ductal and acinar cell neoplasms in Carney complex: a possible new association. J Clin Endocrinol Metab 2011, 96:E1888-1895. 10.1210/jc.2011-1433, 3205895, 21900385.
42. Villeneuve H, Tremblay S, Galiatsatos P, Hamel N, Guertin L, Morency R, Tischkowitz M. Acinic cell carcinoma of the retromolar trigone region: expanding the tumor phenotype in Cowden syndrome?. Fam Cancer 2011, 10:691-694. 10.1007/s10689-011-9472-8, 21822720.
43. Farooq A, Walker LJ, Bowling J, Audisio RA. Cowden syndrome. Cancer Treat Rev 2010, 36:577-583. 10.1016/j.ctrv.2010.04.002, 20580873.
44. Walerych D, Napoli M, Collavin L, Del Sal G. The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis 2012, 33:2007-17. 10.1093/carcin/bgs232, 3483014, 22822097.
45. Santarosa M, Maestro R. BRACking news on triple-negative/basal-like breast cancers: how BRCA1 deficiency may result in the development of a selective tumor subtype. Cancer Metastasis Rev 2012, 31:131-42. 10.1007/s10555-011-9336-6, 22101651.
46. Rhiem K, Flucke U, Engel C, Wappenschmidt B, Reinecke-Lüthge A, Büttner R, Schmutzler RK. Association of the BRCA1 missense variant R1699W with a malignant phyllodes tumor of the breast. Cancer Genet Cytogenet 2007, 176:76-79. 10.1016/j.cancergencyto.2007.03.006, 17574969.
47. Ashida A, Fukutomi T, Tsuda H, Akashi-Tanaka S, Ushijima T. Atypical medullary carcinoma of the breast with cartilaginous metaplasia in a patient with a BRCA1 germline mutation. Jpn J Clin Oncol 2000, 30:30-32. 10.1093/jjco/hyd006, 10770566.
48. Breuer A, Kandel M, Fisseler-Eckhoff A, Sutter C, Schwaab E, Lück HJ, du Bois A. BRCA1 germline mutation in a woman with metaplastic squamous cell breast cancer. Onkologie 2007, 30:316-318. 10.1159/000101515, 17551255.
49. Suspitsin EN, Sokolenko AP, Voskresenskiy DA, Ivantsov AO, Shelehova KV, Klimashevskiy VF. Mixed epithelial/mesenchymal metaplastic carcinoma (carcinosarcoma) of the breast in BRCA1 carrier. Breast Cancer 2011, 18:137-140. 10.1007/s12282-009-0105-0, 19350356.
50. Noël JC, Buxant F, Engohan-Aloghe C. Low-grade adenosquamous carcinoma of the breast-a case report with a BRCA1 germline mutation. Pathol Res Pract 2010, 206:511-513. 10.1016/j.prp.2010.01.008, 20189727.
51. Rashid MU, Shah MA, Azhar R, Syed AA, Amin A, Hamann U. A deleterious BRCA1 mutation in a young Pakistani woman with metaplastic breast carcinoma. Pathol Res Pract 2011, 207:583-586. 10.1016/j.prp.2011.05.011, 21723046.